Content Detail

• Content META

  Title	PetMed Express : Third Quarter 2025 Press Release
  ID	6757635
  External ID	7539757540
  Author	Unknown
  Published Date	Feb. 10, 2025, 3:21 p.m.
  Summary	PetMeds® Announces Third Quarter Fiscal 2025 Financial Results DELRAY BEACH, Fla., Feb. 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS)
  Tags	None
  URL	https://www.marketscreener.com/quote/stock/petmed-express-inc-10442/news/petmed-express-third-quarter-2025-press-release-49012281/
  Sentiment	Negative: 0.00958    Neutral: 0.21734    Positive: 0.77308
  Relevance	0.00760

• Content Details

  Content ID	4200204
  Key	ec724e1e-6c8b-4d57-9cf1-859d714d843e
  Content	PetMeds® Announces Third Quarter Fiscal 2025 Financial Results DELRAY BEACH, Fla., Feb. 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its Third Quarter Fiscal 2025 Financial Highlights Net sales of $53.0 million. Gross margin rate of 28.1%, an increase of 80 basis points compared to the prior year period. Adjusted EBITDA of $2.0 million compared to Adjusted EBITDA of $0.9 million in the prior year period. Continued progress on key initiatives supporting the transformation of the business. "In just nine months, we have made signi strides in our transformation journey, and I am pleased to report that we have delivered meaningful progress across our strategic priorities. Our focused execution is already yielding results, validating our direction and setting the foundation for long-term success. For the third quarter, we achieved $2 million in Adjusted EBITDA, a $1.1 million improvement year-over-year, while successfully reducing G&A expenses by $2.6 million compared to last year. As we continue to build a stronger, more e Time: 4:30 P.M. Eastern Time, February 10, 2025 Public call dial in (877) 407-0789 (toll free) or (201) 689-8562. Webcast stream link: https://investors.petmeds.com for those who wish to stream the call via webcast. Replay: Available until February 24, 2025, at 11:59 P.M Eastern Time. To access the replay, call (844) 512-2921 (toll free) or (412) 317-6671 and enter passcode 13750886. About PetMed Express, Inc. Founded in 1996, PetMeds is a leader in the consumer pet healthcare sector. As a national online retailer with expert pharmacists and licenses across states, PetMeds.com and PetCareRx.com deliver top branded pharmaceuticals, generics, compounded prescription medications and OTC supplements and vitamins that help pets live longer, healthier lives. Leveraging telehealth and insurance partnerships, they o unparalleled value and convenience that enhance wellness and longevity for dogs, cats, and horses. PetMeds and PetCareRx provides Forward Looking Statement This press release may contain "forward-looking statements", within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company's ability to meet the objectives included in its business plan. Important factors that could cause results to di materially from those indicated by such forward-looking statements are set forth in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in the Company's Annual Report on Form 10-K for the year ended March 31, 2024. The Company's future results may also be impacted by other risk factors listed from time to time in the Company's with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company's views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements. PETMEDS INVESTOR RELATIONS CONTACT ICR, LLC John Mills Reed Anderson investor@petmeds.com PETMED EXPRESS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except for share and per share data) PETMED EXPRESS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except for share and per share amounts) (Unaudited) PETMED EXPRESS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) (see below) adjusted EBITDA, a non-GAAP nancial measure that we calculate as net income excluding share-based compensation expense; depreciation and amortization; income tax provision; interest income (expense); and other non-operational expenses. We have provided reconciliations below of adjusted EBITDA to net income, the most directly comparable GAAP We have included adjusted EBITDA, herein, because it is a key measure used by our management and Board of Directors to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the e of non-cash expenses and other expenses. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors. We believe it is useful to exclude non-cash charges, such as share-based compensation expense, depreciation and amortization from our adjusted EBITDA because the amount of such expenses in any speci period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense), as neither are components of our core business operations. We also believe that it is useful to exclude other expenses, including the investment banking fee related to the Vetster partnership, acquisition costs related to PetCareRx, employee severance and estimated state sales tax accrual as these items are not indicative of our ongoing operations. Adjusted EBITDA has limitations as a measure, and these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are: Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized continue to be for the foreseeable future, a material recurring expense in our business and an important part representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs Because of these and other limitations, adjusted EBITDA should only be considered as supplemental to, and alongside with other GAAP based performance measures, including various cash metrics, net income, net margin, and our other GAAP results. The following table presents a reconciliation of net income, the most directly comparable GAAP measure to adjusted EBITDA for each of the periods indicated: Reconciliation of Non-GAAP Measures PetMed Express, Inc. (Unaudited) Consolidated Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA: Included in interest income, net is $0.4 million of interest expense related to the sales tax liability and $0.5 million of interest income for the three months ended December 31, 2024. This compares to $0.4 million of interest expense related to the sales tax liability and $0.6 million of interest income for the three months ended December 31, 2023. Consolidated Reconciliation of GAAP Net Income to Adjusted EBITDA: Included in interest income, net is $1.2 million of interest expense related to the sales tax liability and $1.5 million of interest income for the nine months ended December 31, 2024. This compares to $1.3 million of interest expense related to the sales tax liability and $1.7 million of interest income for the nine months ended December 31, 2023. Source: PetMed Express, Inc. Attachments Original document Permalink Disclaimer PetMed Express Inc. published this content on February 10, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 10, 2025 at
  Content Reference URL	None

• Publisher

  Publisher Name	MarketScreener
  Publisher URL	http://www.marketscreener.com
  Description	None
  Trust Flow Score	23
  Citation Flow Score	26

• Data Source

  Data Source Name	Quantexa News
  Data Source Type	news
  Data Source URL	https://app.aylien.com/dashboard
  Description	Welcome to Quantexa News API — the most powerful way to aggregate, filter, and integrate global news data into your apps and models.
  Weight	10